EDMONTON, Sept. 25, 2019 /CNW/ - OncoQuest Inc., a
privately held, cancer immunotherapy company today announced that a
Notice of Allowance was received from the U.S. Patent and Trademark
Office (USPTO) for patent protection of the schedule of
administration of our monoclonal anti-CA-125 antibody, mAb-B43.13,
now known as oregovomab, in a specific schedule in combination with
carboplatin and paclitaxel in Stage III-IV ovarian cancer
patients.
A Notice of Allowance signifies that the applicant is entitled
to receive patent protection of 20 years under the law. The patent
claim lays out a specific schedule of administration of oregovomab
in combination with carboplatin and paclitaxel, and as a standalone
injection 10 to 14 weeks after the third oregovomab administration.
This administration protocol generated a statistically significant
Progression Free and Overall Survival advantage over chemotherapy
alone in a 97-patient randomized controlled Phase 2 study in newly
diagnosed Stage III-IV ovarian cancer patients which was completed
in 2017 [NCT01616303].
The Company is currently planning to launch a Phase 3 trial in
Q1 2020. The planned Phase 3 study is expected to enroll over 500
patients with newly diagnosed, advanced ovarian cancer globally.
The primary endpoint will be to evaluate progression-free survival
of patients treated with oregovomab plus a standard-of-care
chemotherapy combination, carboplatin and paclitaxel, compared to
the chemotherapy alone.
"We are very pleased that this additional patent was allowed as
it is a significant addition to our oregovomab patent portfolio,
providing extended exclusivity protection, in addition to what we
are already expecting from the Biologics Price Competition and
Innovation Act (BPCIA)," said Dr. Madiyalakan, CEO of OncoQuest.
"This marks an important step in our ongoing efforts to optimize
the value of our oregovomab product as we embark on our initiation
of the Phase III registration study and towards commercialization
of oregovomab."
About OncoQuest
OncoQuest is a subsidiary of Quest PharmaTech Inc. (TSXV-QPT)
("Quest") and is a private biopharmaceutical company focused on the
development and commercialization of immunotherapies for cancer.
OncoQuest's technology platform includes a portfolio of tumor
antigen specific monoclonal immunoglobulins including CA-125, MUC1,
PSA and Her2/neu. The company is exploring the therapeutic
potential of these antibodies in combination with other immune
modulating drugs or drug combinations to enhance tumor specific
immunity and clinical outcomes.
OncoQuest's lead product candidate is oregovomab, an anti-CA-125
antibody, for the treatment of ovarian cancer that has completed a
Phase 2 frontline randomized controlled study. In addition,
oregovomab is currently being studied in multiple Phase 2 clinical
trials in the relapsed recurrent ovarian cancer setting as well.
OncoQuest's anti-MUC1 antibody program has already undergone a
Phase 1 clinical trial in breast cancer patients, and its
development is being led by OncoVent Co. Ltd., OncoQuest's joint
venture partner that has licensed the rights of our
immunotherapeutic antibodies in the territory of Greater China. OncoQuest's next-generation
monoclonal antibodies are based on immunoglobulin E licensed from
UCLA, Stanford
University and Advanced Immune Therapeutics, Inc. These
antigen specific monoclonal IgE antibodies are currently in
preclinical development. To learn more, visit
www.oncoquestinc.com .
About Quest PharmaTech Inc.
Quest PharmaTech Inc is a
publicly traded, Canadian based biopharmaceutical company (QPT:
TSX-V) developing products to improve the quality of life. The
Company through its subsidiary, OncoQuest and its Chinese joint
venture, OncoVent, is developing antibody-based immunotherapeutic
products for cancer. Quest has an ownership interest in Bioceltran
which is focused on SP Technology™ for transdermal delivery of
drugs and photosensitizers for pharmaceutical and cosmetic
purposes. Quest through its subsidiary, Madenco BioSciences, is
developing pharmaceutical products for dermatology and wound
healing applications. Quest, through its ownership interest
in OncoCare Therapeutics, is developing an antibody licensed from
University of Nebraska, AR 9.6 mAb
against truncated O-glycan on MUC16, for targeted cancer therapy
applications. To learn more, visit
www.questpharmatech.com
Forward Looking Statements
This press release
includes forward-looking statements. In some cases,
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions. These statements are based on management's
expectations and assumptions as of the date of this press release
and are subject to a number of risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions from
those set forth or implied by any forward-looking
statements. The information in this release is provided only
as of the date of this release and the company undertakes no
obligation to update any forward-looking statements contained in
this release based on new information, future events, or otherwise,
except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original
content:http://www.prnewswire.com/news-releases/oncoquest-receives-notice-of-allowance-for-patent-protection-of-the-administration-schedule-of-oregovomab-and-chemotherapy-for-stage-iii-iv-ovarian-cancer-patients-300924727.html
SOURCE OncoQuest Inc.